1. Skip to navigation
  2. Skip to content
  3. Skip to footer

Current Issue

2012 May

A new player: Affymax wins approval for a new anemia drug

Renal News

Go
You are viewing articles with topic: clinical
  • ESRD patients face long hemoglobin recovery time after hospitalizations May 17 Most patients with end-stage renal disease experience a drop in hemoglobin after hospitalization, and recovery can be slow, according to data presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
  • USRDS finds jump in blood transfusions for dialysis patients May 11 According to the United States Renal Data System, in each of the first nine months of 2011 when the new payment system took effect, the share of dialysis patients who received blood transfusions increased 9 to 22% over the corresponding months in 2010, The New York Times reports
  • Blood pressure best managed when healthy lifestyle is central to treatment May 11 New approaches to controlling blood pressure are on the horizon, according to a presentation at the 2012 National Kidney Foundation Spring Clinical Meeting – but ultimately, the most powerful step patients can take is to improve their lifestyle, particularly reducing salt intake.
  • Readily available urine dipstick can predict acute kidney injury May 10 An inexpensive and widely used urine dipstick test may provide an easier, more effective way to predict Acute Kidney Injury in patients with sepsis, or severe blood poisoning infections. This research is presented at the National Kidney Foundation's Spring Clinical Meetings.
  • Coordinated care reduces medical costs and improves health of kidney patients May 10 Patients with kidney failure who received collaborative, supportive health services saw better outcomes and lowered medical costs than those who did not receive this continuity of care, according to new research based on the last three years of a Medicare pilot that was presented at the National Kidney Foundation's Spring Clinical Meetings.
  • Socializing between professionals, patients in a dialysis unit can improve patient health May 10 General discussion about lifestyle may be effective in stabilizing and improving lab values, according to new research presented at the National Kidney Foundation's Spring Clinical Meetings held in Washington, DC this week.
  • Dialysis patients given aggressive end-of-life care May 10 Patients on dialysis are subject to much more intensive medical care in the last month of life than are patients dying of cancer or heart failure, said an analysis of Medicare data that is raising concerns about the end-of-life care that patients with end-stage renal disease receive, American Medical News reports.
  • First Health Care Innovation award winners include peritoneal dialysis project May 9 Health and Human Services Secretary Kathleen Sebelius announced the first batch of organizations for the new Health Care Innovation awards, which were created as part of the Affordable Care Act. The awards will support 26 innovative projects nationwide that HHS says will save money, deliver high quality medical care and enhance the health care workforce. The preliminary awardees announced are expected to reduce health spending by $254 million over the next three years.
  • New equation is better predictor of kidney disease risk May 8 A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that the new CKD-EPI equation for calculating GFR is a better predicator of risk for kidney disease and death compared to the most widely used method.
  • Rockwell to start clinical trial that aims to reduce need for ESAs with SFP May 1 Rockwell Medical has completed patient enrollment in its PRIME clinical study, which is designed to investigate the reduction in the need for erythropoietin-stimulating agents in hemodialysis patients receiving Soluble Ferric Pyrophosphate (SFP) via dialysate.
  • Hemodiafiltration does not improve survival or heart health, but intense treatments may help April 27 A technique that removes additional toxins during dialysis does not improve kidney failure patients' survival or heart health, but intense treatments may provide a benefit, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.
  • Takeda's diabetes drug rejected by FDA April 27
  • NKF: Kidney disease screening is valuable for those at risk April 24 A new report published this month in the Annals of Internal Medicine, questioned whether widespread screening for chronic kidney disease is worthwhile. Authors said there have been no studies on the benefits or harms of population-wide screening for chronic kidney disease. When reviewing the literature, however, they did find evidence that certain treatments can slow the progression of the disease.
  • FDA OKs new AstraZeneca hypertension drug April 13 AstraZeneca plc said that the U.S. Food and Drug Administration has approved its blood pressure medication Dutoprol, and the drugmaker said it plans to ship the drug directly to patients.
  • CMS gives Affymax's Omontys special reimbursement code April 13 Affymax Inc. and Takeda Pharmaceuticals said Friday that the Centers for Medicare & Medicaid Services created a special reimbursement code, a Q-code, for their new anemia drug Omontys.
  • Anemia treatment patterns have changed for dialysis and CKD patients April 12 The use of erythropoietin stimulating agents to treat anemia in dialysis patients has changed considerably in the period immediately following the implementation of the Prospective Payment System for the End-Stage Renal Disease program and appears to have somewhat stabilized in early 2012, according to a new report from BioTrends. But anemia treatment changes in the chronic kidney disease setting were more dramatic in a year to year analysis, due largely to the label change that occurred in 2011
  • Affymax gets $50 million milestone payment from Takeda April 10 Affymax, Inc. announced that it has received a $50 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize Omontys (peginesatide) Injection.
  • Akebia successfully completes Phase 2 anemia drug study April 10 Akebia Therapeutics Inc., has successfully completed a randomized, double-blinded, placebo-controlled Phase 2 dose-ranging study of AKB-6548 in patients with stage 3 and 4 chronic kidney disease.
  • FDA chooses three ESRD products for new Innovation Pathway program April 9 The U.S. Food and Drug administration has chosen three products for patients with end stage renal disease to participate in the Innovation Pathway, a new system designed to help medical devices reach patients in a safe, timely, and collaborative manner.
  • DCI, Tennessee health department begin study to improve infection detection in hemodialysis patients April 9
NEWER
OLDER